AdaptHealth Corp. (NASDAQ: AHCO) – SVB Leerink equity researchers released their Q3 2021 EPS estimates for AdaptHealth in a research note to investors on Monday, September 27. SVB Leerink analyst W. Mayo expects the company to earn $ 0.38 per share for the quarter. SVB Leerink has an “Outperformance” rating and a target price of $ 30.00 on the stock. SVB Leerink also released estimates for AdaptHealth’s fourth quarter 2021 earnings at $ 0.43 EPS, FY2021 earnings at $ 1.36 EPS, Q1 2022 earnings at $ 0.35 EPS, Q2 2022 earnings. at $ 0.45 EPS, Q3 2022 earnings at $ 0.44 EPS, Q4 2022 earnings at $ 0.49 EPS, FY2022 earnings at $ 1.73 EPS, year 2023 earnings at 1, EPS $ 96, FY2024 earnings $ 2.30 EPS, and FY2025 earnings $ 2.73 EPS.

Several other equity research analysts also recently published reports on the stock. Zacks Investment Research downgraded AdaptHealth shares from a “hold” rating to a “sell” rating in a research note on Wednesday, August 25. TheStreet downgraded AdaptHealth from a “c-” rating to a “d” rating in a research report on Monday, August 23. Finally, Robert W. Baird downgraded AdaptHealth from a “neutral” to an “outperforming” rating and increased its price target for the company from $ 30.00 to $ 36.00 in a published research report. Wednesday July 14. Two research analysts rated the stock with a sell rating and nine issued a buy rating for the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $ 43.00.

AHCO shares opened at $ 23.40 on Wednesday. AdaptHealth has a one-year minimum of $ 20.76 and a one-year maximum of $ 41.58. The company has a 50-day moving average of $ 23.71 and a two-hundred-day moving average of $ 27.31. The stock has a market cap of $ 3.06 billion, a price-to-earnings ratio of -49.79, a PEG ratio of 0.37, and a beta of -0.09. The company has a debt ratio of 0.95, a current ratio of 0.98, and a quick ratio of 0.84. AdaptHealth (NASDAQ: AHCO) last released its results on Wednesday, August 4. The company reported earnings per share of $ 0.12 for the quarter, missing Zacks’ consensus estimate of $ 0.29 ($ 0.17). AdaptHealth had a return on equity of 8.18% and a net margin of 2.40%. The company posted revenue of $ 617.00 million for the quarter, compared to analysts’ estimates of $ 574.03 million. AdaptHealth’s revenue for the quarter increased 165.8% compared to the same quarter last year.

Hedge funds and other institutional investors have recently changed their positions in the company. Commonwealth Equity Services LLC increased its holdings in AdaptHealth shares by 40.8% in the first quarter. Commonwealth Equity Services LLC now owns 23,162 shares of the company valued at $ 851,000 after acquiring an additional 6,706 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in AdaptHealth by 28.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 28,395 shares of the company valued at $ 1,044,000 after purchasing an additional 6,219 shares during the period. Alliancebernstein LP increased its stake in AdaptHealth shares by 108.1% in the first quarter. Alliancebernstein LP now owns 91,799 shares of the company valued at $ 3,375,000 after purchasing an additional 47,690 shares during the period. Rhumbline Advisers increased his holdings of AdaptHealth shares by 196.1% in the first quarter. Rhumbline Advisers now owns 75,457 shares of the company valued at $ 2,774,000 after purchasing an additional 49,975 shares during the period. Finally, American International Group Inc. increased its position in AdaptHealth by 201.3% during the first quarter. American International Group Inc. now owns 43,766 shares of the company valued at $ 1,609,000 after acquiring an additional 29,239 shares in the last quarter. Institutional investors and hedge funds hold 50.87% of the company’s shares.

AdaptHealth Company Profile

AdaptHealth Corp. engages in the provision of home health care equipment, supplies and related services. It focuses on sleep therapy equipment for people with obstructive sleep apnea (OSA), home medical equipment for patients discharged from acute care and other facilities, oxygen and services related chronic therapy in the home; and HME medical devices and supplies on behalf of the chronically ill. sick patients with diabetes care, wound care, urology, ostomy and nutritional supply needs.

Recommended Story: What’s the Definition of a Trade War?

This instant news alert was powered by storytelling technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in AdaptHealth now?

Before you consider AdaptHealth, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and AdaptHealth was not on the list.

While AdaptHealth currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here